NiKang Therapeutics’ US$200 Million Equity Financing

Sidley Austin LLP advised the lead investors on the deal.

HBM Healthcare Investments, Cormorant Asset Management, and Octagon Capital Advisors, with participation from a syndicate of other leading institutional investors, acted as lead investors in NiKang Therapeutics Inc.’s US$200 million equity financing pursuant to the issuance and sale of its Series C Preferred Stock. 

NiKang is a clinical-stage biotech company focused on developing innovative small molecule oncology medicines to help patients with unmet medical needs.

The Sidley team is led by Mehdi Khodadad (M&A and Private Equity, Picture) and includes Anthony Friedman, Patrick Sims, and Max Chaffetz (M&A and Private Equity).

Involved fees earner: Max Chaffetz – Sidley Austin LLP; Anthony James Friedman – Sidley Austin LLP; Mehdi Khodadad – Sidley Austin LLP; Patrick Sims – Sidley Austin LLP;

Law Firms: Sidley Austin LLP;

Clients: Cormorant Asset Management; HBM Healthcare Investments; Octagon Capital;

Author: Martina Bellini